State Street Holds 4.7% Of MannKind Without Seeking To Influence Its Control

The holding covered 15,096,712 shares at September 30, with MannKind executives scheduled for London investor updates.

Share
State Street Holds 4.7% Of MannKind Without Seeking To Influence Its Control

State Street reported a 4.7% stake in MannKind, which develops and sells treatments for diabetes, fluid overload and rare lung diseases, in a passive ownership disclosure filed Tuesday. The holding covered 15,096,712 common shares as of September 30, 2026, rather than a purchase dated to the filing day.

A Passive Holding, Shared Voting Power

State Street certified that the investment arose from ordinary business activity and that it holds the securities without a purpose or effect of changing or influencing MannKind's control.

The holder reported shared voting power covering 14,316,800 shares. Its shared authority to sell or otherwise dispose of stock covered 15,096,712 shares. State Street reported zero sole voting power and zero sole disposal power.

Insulin, At-Home Treatment And Lung Royalties

MannKind's cardiometabolic products include Afrezza, an inhaled insulin taken at mealtimes by adults with diabetes; Furoscix, a furosemide injection administered at home using an on-body infusor; and V-Go, a wearable device that delivers insulin. MannKind handles U.S. sales of all three itself. Its treatment focus includes fluid overload associated with heart failure and chronic kidney disease.

The lung business uses a different commercial arrangement. United Therapeutics sells Tyvaso DPI, an inhaled pulmonary hypertension treatment, while MannKind receives royalties on net sales and revenue for supplying it.

MannKind produces the powders for Afrezza and Tyvaso DPI in Danbury, Connecticut. Its Indian partner, Cipla, received an initial shipment of Afrezza in December 2025.

London Business Updates Come Next

MannKind announced Tuesday that CEO Michael Castagna and CFO Chris Prentiss are scheduled to deliver business updates at investor conferences in London.

The appointments are the UBS Global Biopharma Conference on November 17 and the Jefferies Global Healthcare Conference on November 18.

Sources

More on MannKind

All MannKind (MNKD) coverage →